Phathom Pharmaceuticals, Inc. (PHAT) Form 8-K — Apr 30, 2026
Phathom Pharmaceuticals reported first quarter 2026 financial results with net revenues of $58.3 million, a 104% increase compared to the prior year. The company achieved approximately 1.35 million total VOQUEZNA prescriptions filled to date, reflecting the success of its commercial strategy and sales force expansion. The company significantly reduced operating expenses to $61.8 million, down approximately 43% year-over-year, resulting in a net loss of $30.4 million compared to $94.3 million in the same period last year. Cash and cash equivalents stood at $180.9 million as of March 31, 2026, bolstered by a public equity offering in January 2026 and subsequent debt repayment.
Key figures
- Revenue
- 58.3 million
- Guidance
- $320–$345 million
- Net Income
- (30.4 million)
- Revenue Yoy
- 104%
- Cash Position
- 180.9 million
Price after filing
Close on the filing date to close N calendar days later (from $11.20). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.